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Background: Total glucosides of paeony (TGP) is a biologically active compound extracted from Paeony root. TGP
has been used in rheumatoid arthritis therapy for many years. However, the mechanism by which TGP prevents
bone loss has been less explored.
Methods: TGP was orally administered for 3 months to New Zealand rabbits with antigen-induced arthritis (AIA).
Digital x-ray knee images and bone mineral density (BMD) measurements of the subchondral knee bone were
performed before sacrifice. Chondrocytes were observed using transmission electron microscopy (TEM). Histological
analysis and mRNA expression of receptor activator of nuclear factor-B ligand (RANKL) and osteoprotegerin (OPG)
were evaluated in joint tissues.
Results: The BMD value in TGP rabbits was significantly higher compared with that seen in the AIA model rabbits.
In addition, the subchondral bone plate was almost completely preserved by TGP treatment, while there was a
decrease in bone plate integrity in AIA rabbits. There was less damage to the chondrocytes of the TGP treated
group. Immunohistochemical examination of the TGP group showed that a higher percentage of TGP treated
chondrocytes expressed OPG as compared to the chondrocytes isolated from AIA treated animals. In contrast,
RANKL expression was significantly decreased in the TGP treated group compared to the AIA group. In support of
the immunohistochemistry data, the expression of RANKL mRNA was decreased and OPG mRNA expression was
enhanced in the TGP group when compared to that of the AIA model group.
Conclusion: These results reveal that TGP suppresses juxta-articular osteoporosis and prevents subchondral bone
loss. The decreased RANKL and increased OPG expression seen in TGP treated animals could explain how
administration of TGP maintains higher BMD.
Keywords: Juxta-articular, Osteoporosis, Rheumatoid arthritis, Receptor activator of nuclear factor-B ligand, Total
glucosides of paeonyBackground
Rheumatoid arthritis (RA) is characterized by chronic
inflammation which eventually leads to cartilage degrad-
ation and subsequent bone destruction [1]. Bone damage
can be either localized, as in juxta-articular bone loss, or
more systemic as in generalized bone loss [2]. There are
different molecular mechanisms governing systemic bone
loss and juxta-articular bone loss [3]. Juxta-articular bone
loss mainly occurs in the subchondral bone with synovial
tissue invasion of the adjacent cartilage [4]. Although
juxta-articular bone loss represents an early feature of RA,* Correspondence: czz1509@126.com
Department of Orthopaedics and Traumatology, Shanghai Municipal Hospital
of Traditional Chinese Medicine, Shanghai University of TCM, 200071,
Shanghai, China
© 2013 Chao Wei et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the orvery little is known about pathogenesis of juxta-articular
bone loss in RA.
Osteoblastic bone formation and osteoclastic bone re-
sorption are involved in the regulation of bone homeosta-
sis [5]. Osteoclasts are the principal instruments of bone
destruction. Osteoclasts are regulated through a differenti-
ation process primarily governed by two key cytokines,
namely macrophage colony-stimulating factor (M-CSF)
and receptor activator of nuclear factor-B ligand (RANKL)
[6]. RANKL promotes osteoclast differentiation and plays
an important role in the joint destruction seen in arthritis.
Osteoprotegerin (OPG) regulates the pro-osteoclastogenic
actions of RANKL, which prevents it from binding to and
activating RANK.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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formation and resorption is observed [7]. Recent study
have shown that in AIA rabbits, RANKL enhanced
osteoclastogenesis may contribute to the development of
juxta-articular loss, demonstrating the importance of
RANKL in the bone destruction associated with RA [8].
Any imbalance between RANKL and OPG may lead to
osteoarticular pathology. In particular, an increase of
RANKL and a deficiency of OPG expression results in
bone erosion [9,10]. In RA, overexpression of RANKL
can induce synovial macrophage differentiation into ac-
tive osteoclasts, leading to bone destruction. RANKL
also plays a key role in the regulation of dendritic cell
survival, lymphocyte development, and lymph node or-
ganogenesis [11]. The inhibition of bone resorption by
the regulation of the RANKL/OPG balance has been
demonstrated in postmenopausal women [12]. Treat-
ment with suppressive factor RANKL resulted in an in-
creased amount of bone mineral density (BMD) [13].
High BMD loss in RA patients was associated with joint
damage progression, even in the early stages of RA [14].
In summary, inhibition of RANKL expression not only
prevents juxta-articular bone loss, but also prevents joint
destruction in RA patients.
Non-steroidal anti-inflammatory drugs and biologics
are commonly used to alleviate the symptoms of RA
[15]. However, there are severe adverse reactions associ-
ated with the prolonged use of these drugs [16]. There-
fore, it is essential to continue the search for new
therapeutic agents to treat RA. In Asia, patients com-
monly try complementary methods of treatment for RA
[17]. Natural plant derived products with therapeutic po-
tential have received substantial attention [18].
Total glucosides of paeony (TGP) is an active compound
extracted from the paeony root. TGP is mainly composed
of paeoniflorin, with paeoniflorin accounting for appro-
ximately 90% of the active constituents of TGP. TGP has
been reported to have a clinically significant therapeutic
effect on RA, and is becoming more widely used to treat
RA [19]. Extensive studies have shown that TGP exhibits
anti-inflammatory, analgesic, and immunoregulatory ac-
tivities [20]. Chang et al. found that TGP exerted its
anti-inflammatory effects by inhibiting the production of
pro-inflammatory mediators in synoviocytes [21]. Further-
more, Xu et al. showed that the ability of TGP to mediate
the levels of IL-1, TNF alpha, IL-6, and PGE in
synoviocytes is responsible in part for its inhibition of RA
progression [22]. In addition, TGP has been reported to
have protective effects on joint destruction. He et al.
showed that the protective effect of paeoniflorin might be
associated with inhibiting the production of matrix
metalloproteinases MMP-1 and MMP-3 by fibroblast-like
synoviocytes [23]. These reports have raised the possibility
that TGP could prevent juxta-articular osteopenia in RA.In the present study we investigated the effect of the
TGP on juxta-articular osteopenia and subchondral bone
destruction. We set out to further our understanding of
the mechanisms underlying the therapeutic actions of
TGP. In this report we provide experimental evidence to
support further development of TGP for clinical use in
the treatment of RA.
Methods
Drugs and animals
Total glucosides of paeony (TGP) was purchased from
Liwah Plant Extraction Technology Co., Ltd Zhejiang
Province, China. Indomethacin (IND) was used as a
positive control. Each tablet contained 25 mg indometh-
acin (supplied by Hebei Jizhong Pharmaceutical Co. Ltd.,
China).
New Zealand rabbits with a body weight of 3–3.5 kg,
were obtained from the Shanghai Laboratory Animal
Center of the Chinese Academy of Sciences. AIA rabbits
were induced as in earlier studies [24]. Briefly, rabbits
were injected intradermally with 4 mg ovalbumin (OVA)
in Freund’s complete adjuvant (Sigma Chemical Co., St.
Louis, MO, USA). This injection procedure was repeated
once a week, twice in total. 4 weeks after the last injec-
tion of OVA-CFA, the knee joints were injected with
1 ml of OVA once a week. Six weeks after the last
booster injection, AIA rabbits were graded by scoring
clinical signs according to criteria described previously
[25]. The rabbits with a total score of clinical signs
higher than six that showed established arthritis were
randomly divided into three groups: The AIA model
group (n = 5), TGP group (n = 5) and IND group (n = 5).
The normal group rabbits (n = 5) did not undergo a pro-
cedure. All rabbits were housed under standard labora-
tory conditions. The rabbits in the TGP group received
intragastric (i.g.) administrations of TGP at 60 mg/kg
per day. Rabbits in the IND group received i.g. adminis-
trations of IND at 3 mg/kg per day. Both dosages are
equivalent to 10 times the clinical dosage for a 60 kg
adult. The duration of drug treatment was for a period
of 3 months. Rabbits in the normal and AIA model
groups received the same volume of normal saline. Rab-
bits were anaesthetized and sacrificed after 3 months.
Articular cartilage and subchondral bone were collected
from knee joints of rabbits after being euthanized. This
protocol received approval by the committee for Animal
Experiments of the University Medical Centre, Shanghai,
China.
Radiographic analysis and bone mineral density
measurements
Before being euthanized, radiographic analysis and bone
mineral density measurements were used to determine
the presence of juxta-articular osteoporosis in rabbit
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croradiography system (Softex, Tokyo, Japan), at 40 kV
and 3 mA for 75 s. Rabbits were placed in the supine
position and the x-ray beam was centered over the
femorotibial joints [26]. To measure the BMD of rabbit’s
juxta-articular bone, all rabbits underwent dual energy
x-ray absorptiometry scanner (DEXA, Hologic Inc.,
Waltham, MA). Rabbits were placed in the supine pos-
ition and the knee joint was measured by BMD. BMD
measurements were conducted on the medial femoral
condyles and tibial plateaus.
Histological assessment of cartilage destruction and
subchondral bone thickness
The proximal tibia was cut into 5 μm thick frontal sec-
tions for histomorphometry. The sections were stained
with Safranin O-fast green. The Mankin grading system
was used to evaluate cartilage destruction by two inde-
pendent pathologists [27]. The width of the subchondral
bone plate was measured between the tidemark of articu-
lar cartilage and subchondral bone ends. Subchondral
bone plate thickness was evaluated in three different re-
gions of the femur condyle at × 100 magnification.
Electron microscopy
After demineralization, tissue specimens were placed in
2.5% glutaraldehyde in Sorenson’s phosphate buffer and
rinsed in buffer and decalcified in a controlled manner
using 10% EDTA. We then used an increasingly concen-
trated series of ethanol solutions to dehydrate. Each spe-
cimen was embedded in Epon812 for transmission
electron microscopy (TEM). Tissue sections were cut to
60 nm thickness and subsequently double stained se-
quentially using uranyl and then phosphotungstic acid.
We then performed TEM to observe chondrocytes
(HITACHI H-500, Japan).
Immunohistochemical analysis of RANKL and OPG
expression in subchondral bone
5 μm thick sections were used for immunohistochemical
examinations. The sections were incubated with primary
antibodies for OPG (1:50 dilution) and RANKL (1:100
dilution0 [Santa Cruz]. After staining the nucleus with
DAPI, the slices were then stained with Cy3-labeled sec-
ondary antibodies for 1 h at 37°C. Negative control
staining was performed using PBS instead of the primary
antibody.
Quantitative real time PCR analysis of RANKL mRNA and
OPG mRNA
Total RNA was extracted from subchondral bone and
cartilage in the tibiae articular using Trizol reagent. Two
microliters of each sample was used for real-time PCR
in a Rotor-Gene 2000 system (Australia), which wasperformed as described previously [28]. Relative quanti-
tation was calculated using delta cycle threshold relative













All results were expressed as mean and standard devi-
ation (SD). Measurement data were analyzed using a
one-way analysis of variances (ANOVA, SPSS 11.0).
Ridit analysis was used in order to rank data. A result of
p < 0.05 was considered to be statistically significant.
Results
Effect of TGP inhibition in juxta-articular osteopenia
The AIA group rabbits exhibited juxta-articular bone
osteopenia and the joint space was narrowed in the
knees as evidence by radiographic analysis. However, less
bone loss occurred in the TGP treated group (Figure 1).
The BMD was lower in AIA rabbits as compared to
healthy controls. The difference in BMD between AIA
and control rabbits reached statistical significance (p =
0.022). However, the BMD value in TGP treated rabbits
was significantly higher compared with that in the un-
treated AIA group (p = 0.031). Furthermore, we also ob-
served that the IND positive control group had a higher
BMD than AIA rabbits, although this result did not at-
tain statistical significance (Figure 1E).
TGP reduces arthritis cartilage and subchondral
bone damage
Results showed that in the AIA group, there was a loss of
Safranin O-fast green staining accompanying cleft for-
mation. In addition discontinuous bone trabeculae were
present in the subchondral bone and blood vessel forma-
tion occurred within the osteochondral junction. We have
observed a decrease in the thickness of the subchondral
bone plate compared with those healthy ones (Figure 2).
This difference in subchondral bone plate thickness
reached statistical significance (p = 0.039). However, the
subchondral bone plate was almost completely preserved
in the TGP treated groups, and was partially preserved in
the IND group. Quantitative evaluation of the width of the
subchondral bone plate showed a significant difference
Figure 1 Representative X-ray photographs of knee bone and BMD of knees in each group of rabbits. (A) Normal group (B) AIA group
(C) TGP group (D) IND group (E): Densitometric analysis of bone mineral density (BMD, g/cm2) in the subchondral bones for each group of
rabbits. Results are presented as mean ± S.D.
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0.033) (Figure 2E). Furthermore, the tidemark was dupli-
cated in TGP treated cartilage (Figure 2F). The Mankin
score was significantly higher in AIA rabbits (p = 0.001) as
compared to that exhibited in healthy animals. There was
a significantly lower Mankin score in the TGP treated
group compared with the AIA group (p = 0.003), and no
statistically significant differences in the Mankin score be-
tween the IND and AIA group (p = 0.061) (Figure 2G).
Effect of TGP on chondrocytes
Representative TEM micrographs of chondrocytes are
shown in Figure 3. At the end of the 3th mouth, we
observed a normal cytoplasm contains a euchromatic nu-
cleus. A region of their plasma membranes bears some rela-
tively long filopodia and there were abundant rough
endoplasmic reticulum, numerous well shaped Golgi bodies
and mitochondria located in the cytoplasm. Chondrocytes
in the AIA group displayed a different ultrastructure. AIA
chondrocytes displayed a region of plasma membrane
which bears some relatively short filopodia, typical vacuoles
were abundant in the cytoplasm whereas rough endoplas-
mic reticulum, Golgi bodies and mitochondria were
strongly reduced. However, in the TGP treated group, TEM
micrographs of deep zone chondrocytes showed that their
cytoplasms contain a euchromatic nucleus. A strong reduc-
tion of the number of vacuoles and an abundant presence
of rough endoplasmic reticulum, well shaped Golgi bodies,
and mitochondria were observed in TGP chondrocytes.
The filopodia present on the surface of the chondrocyteswere larger and wider in the TGP group compared with
that in the AIA group.
Inhibition of RANKL and enhanced OPG expression in
cartilage are associated with TGP therapy
Immunohistochemical detection showed that RANKL
and OPG expression were expressed in very few cells in
normal group cartilage. However, AIA rabbits exhibited
higher expression of RANKL with higher intensity
throughout the articular cartilage, with an increase in
intracellular RANKL expression in, both cartilage and
subchondral bone. There were very few cells expressing
OPG in AIA rabbit cartilage. In the TGP group, RANKL
expression was significantly decreased in the cartilage.
Nevertheless, OPG expression had higher positive stain-
ing compared with that seen in the AIA group. In the
cartilage of IND rabbits, an increase in the intensity of
the RANKL staining was observed (Figure 4).
Quantitative RT PCR analysis indicated that the
expression of RANKL and OPG mRNA species are low
in the normal group, while the expression of RANKL in-
creases significantly in the AIA group in comparison
with that of normal group (p = 0.014); The expression of
RANKL mRNA in the TGP treated group was signi-
ficantly decreased. In contrast, an enhanced expression
of OPG mRNA was expressed in the TGP group as com-
pared with that in AIA group after administration (p <
0.01). Although the RANKL mRNA level in IND group
tended to be reduced by IND treatment as compared with
that in AIA group, there was no significant difference (p =
Figure 2 Histological evaluation of juxta-articular subchondral bone plate thickness and cartilage damage. Safranin O-fast green stained
sections of subchondral bone (A) Normal group. The width of the subchondral bone measurements was measured in three regions of the femur
condyle. (B) AIA group (C) TGP group (D) IND group (original magnification × 100). (E) Subchondral bone plate thickness in each group of
rabbits. Results are presented as mean ± S.D. (F) The tidemark is duplicated in TGP cartilage (original magnification × 300). (G) Mankin score of the
rabbit cartilage in each group. Results are presented as mean ± S.D.
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normal group, the RANKL/OPG ratio in articular cartil-
age showed an increase in AIA group (p = 0.001). An in-
creased ratio, however, was not found in TGP group
when compared with AIA group (p = 0.011). In addition,
the RANKL/OPG ratio between the IND group and
AIA group, there was no significant difference (p =
0.092) (Figure 5C).
Discussion
Rheumatoid arthritis is a systemic autoimmune inflam-
matory disease involving the breakdown of cartilage andjuxta-articular bone. Patients with RA have irreversible
bone destruction and a poor functional outcome [29].
Therefore, preventing bone destruction is important for
RA therapy. In this study, we demonstrated that TGP
has an inhibitory effect on juxta-articular osteopenia and
subchondral bone destruction.
The subchondral bone plays a crucial role in the patho-
genesis of RA [30]. In our study, TGP fed rabbits
maintained higher BMD in the juxta-articular space com-
pared with AIA rabbits. These findings are of great inter-
est considering juxta-articular bone destruction represents
an early feature of RA [31]. However, the pathogenesis of
Figure 3 TEM micrographs of chondrocytes. (A) Normal group. Healthy normal chondrocytes contain a euchromatic nucleus, very abundant
rough endoplasmic reticulum, and long filopodia (× 10,000 magnification). (B) AIA group. AIA chondrocytes exhibit short filopodia and show a
reduction in the number of Golgi bodies and rough endoplasmic reticulum. (C) TGP group. TGP chondrocytes have a strong reduction of the
number of vacuoles. The fibrosis on the surface of the cartilage was larger and wider (× 15,000). (D) IND group. Chondrocytes from this group
had an abundance of vacuoles, similar to what was seen in the AIA group (× 20,000) (F, filopodia; N, euchromatin nucleus; RER, rough
endoplasmic reticulum).
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explored. The subchondral bone consists of the sub-
chondral bone plate and the subarticular spongiosa. The
tidemark is the boundary between the deep cartilage layer
and the calcified cartilage layer, and is visible as a baso-
philic line [32]. In RA, the disruption of the tidemark pro-
duces cross-talk between the subchondral bone and
cartilage [33]. Articular chondrocytes near the joint surface
will produce factors such as vascular endothelial growth
factor, which may aggravate subchondral tissues and other
locations in the joint [34]. In this study, we also found the
development of blood vessels within the osteochondral
junction in AIA rabbits. The presence of blood vessels be-
yond the tidemark may contribute to bone erosion.
The protective barrier between intra-articular and
subchondral compartments was removed by loss of
osteochondral integrity. Other investigators have shown
that osteochondral angiogenesis and channels invading
the cartilage in RA have been associated with nerve
growth factor expression. Nerve growth factor induces
functional and structural changes within the cartilage
that may contribute to the pain associated with RA [35].Therefore, treatments targeted at the subchondral bone
have the potential to improve palliative care of RA
patients. In this study, we found that the tidemark is du-
plicated in TGP group cartilage. This abnormality indi-
cates that the mineralization process took place in the
cartilage chondrocytes. Chondrocyte hypertrophy and
extracellular matrix mineralization may result in tide-
mark duplication.
In the present study, the TEM micrographs of arthritis
cartilage showed degeneration in the chrondrocytes from
the AIA group and failure to develop significant numbers
of important cytoplasmic organelles. The degenerate chon-
drocytes showed a strong reduction in cytoplasmic rough
endoplasmic reticulum, Golgi bodies, and mitochondria.
Previous studies showed that the degeneration of chon-
drocytes was caused by a deficiency in Golgi apparatus de-
velopment, which could be in charge of sugar synthesis and
protein transport in chondrocytes [36]. However, in the
TGP rabbits, there was less damage in the chondrocytes.
This result suggests that inhibition of chondrocytes degen-
eration might be one of the important mechanisms by
which TGP prevents juxta-articular bone destruction.
Figure 4 RANKL and OPG expression in articular cartilage and subchondral bone. Histological sections were submitted for
immunohistochemical analyses. RANKL staining is shown in each group in Figure 4 (A-D): (A) Normal group. RANKL immunolabeling was rarely
detected. (B) AIA group. RANKL immunolabeling was detected at high levels, especially in subchondral bone. (C) TGP group. TGP decreased
RANKL expression. (D) IND group. OPG staining for each group is shown in Figure 4 (E-H): (E) Normal group. OPG was expressed only in deep
zone. (F) AIA group (G) TGP group. OPG was highly expressed in subchondral bone. (H) IND group (original magnification × 400).
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duction, osteoclastogenesis and bone erosion. IL-17 is
produced mainly by pro-inflammatory T-helper subset
(Th17) cells and both IL-17 and Th17 cells are deeply
implicated with the pathogenesis of RA [37]. IL-17 en-
hances local inflammation and increases the production
of inflammatory cytokines, such as tumor necrosis fac-
tor (TNF)-α, IL-1, and IL-6, which further promote
RANKL expression and activity [38]. In previous stud-
ies, it has been confirmed that TGP treatment signifi-
cantly decreased percentage and number of Th1 andTh17 cells in collagen induced arthritis [39]. Moreover,
treatment with TGP decreased expression of T-bet as
well as phosphorylation of signal transducer and activa-
tor of transcription 1 (STAT1) and STAT3 [39].
To further understand the mechanisms underlying
protective effects of TGP against the development of
arthritis, we evaluated the expression of RANKL and
OPG. Previous studies have associated osteoblast mat-
uration with gene expression levels of RANKL and
OPG [40]. RANK and RANK ligand factors are critical
for controlling osteoclast differentiation and bone
Figure 5 TGP treatment decreases RANKL expression and increases OPG expression. (A) RANKL mRNA and (B) OPG mRNA expression in
each experimental group. (C) RANKL/OPG ratio. Results are presented as mean ± S.D.
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subchondral bone alterations in RA [41]. Thus, abnor-
mally high levels of RANKL are regarded as good bio-
markers for pathogenesis of RA bone damage [42]. In this
study, the expression of RANKL was higher in the articu-
lar cartilage of rabbits with AIA. After administration of
TGP, we found lower expression of RANKL, and higher
expression of OPG compared to those seen in AIA rabbits.These results suggested that reduced levels of RANKL,
along with increased OPG levels could lead to a decrease
in osteoclastogenesis and osteoclast activity, which results
in inhibition of osteoclastic bone resorption and eventually
higher bone mass and BMD in TGP fed rabbits. The re-
sults show that action of TGP on regulating juxta-articular
osteoporosis might be through inhibiting expression of
RANKL, thus altering the RANKL/OPG ratio.
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The overall results revealed for the first time that TGP
could suppress juxta-articular osteoporosis and prevent
subchondral bone destruction. This study also determined
that TGP maintains a higher BMD in part due to altering
the RANKL/OPG ratio.
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